Changing patterns of opioid agonist therapy prescribing in a network of specialised clinics providing care to people with opioid use disorder in Victoria, Australia, 2015 to 2023
Authors:
- Joshua DaweJDJoshua Dawe
- Jason AsselinJAJason Asselin
- Paul DietzePDPaul Dietze
- the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood Borne Viruses and Sexually Transmissible Infections (ACCESS)T(the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance of Blood Borne Viruses and Sexually Transmissible Infections (ACCESS)
Open Access
- 26 March 2025
- journal article
- Published by Wiley in Drug and Alcohol Review
- Vol. 44 (4) , 983-989
Abstract
Introduction: Long‐acting injectable buprenorphine (LAIB) reduces the frequency of contact with opioid agonist therapy (OAT) service providers. Limited data exist on OAT prescribing in Australia after the introduction of subsidised LAIB prescribing in September 2019. This ecological study describes trends in OAT prescribing between 2015 and 2023 across a network of primary care services in Victoria, Australia.Methods: We utilised electronic medical records from 17 clinics in Victoria that provide services to people with opioid dependence to describe OAT prescribing patterns. We described the annual number and type (methadone, buprenorphine, LAIB) of OAT prescriptions issued, individuals prescribed, and individuals initiating OAT. Interrupted time series assessed changes in quarterly OAT prescribing following the introduction of LAIB.Results: Between 2015 and 2023, the average annual number of OAT prescriptions issued, and the average number of recipients prescribed OAT were 47,648 and 6470, respectively. Between 2020 and 2023, the proportion of individuals initiating on LAIB increased from 7% (73/1078) to 31% (357/1146). There was increasing quarterly OAT prescribing before the introduction of LAIB, after which methadone and buprenorphine prescribing declined by 2.6% (CR 0.974; 95% CI 0.968–0.980) and 3.2% (CR 0.968; 95% CI 0.963–0.973), respectively. After being introduced, quarterly LAIB prescribing increased by 13.1% (CR 1.131; 95% CI 1.096–1.167).Discussion and Conclusions: We found substantial changes in OAT prescribing patterns in Victoria between 2015 and 2023, with shifts away from oral methadone and sublingual buprenorphine to LAIB. Alongside ongoing monitoring of prescribing patterns, future research should assess how LAIB impacts patient health and social outcomes.Keywords
Funding Information
- Department of Health and Aged Care, Australian Government
This publication has 13 references indexed in Scilit:
- Trends in use of medicines for opioid agonist treatment in Australia, 2013–2022International Journal of Drug Policy, 2023
- Can a new formulation of opiate agonist treatment alter stigma?: Place, time and things in the experience of extended-release buprenorphine depotInternational Journal of Drug Policy, 2022
- Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependenceInternational Journal of Drug Policy, 2022
- Tracing the affordances of long-acting injectable depot buprenorphine: A qualitative study of patients’ experiences in AustraliaDrug and Alcohol Dependence, 2021
- Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual BuprenorphineJAMA Network Open, 2021
- Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross‐sectional study in three Australian citiesAddiction, 2020
- Reflection on modern methods: a common error in the segmented regression parameterization of interrupted time-series analysesInternational Journal of Epidemiology, 2020
- Opioid use disorderNature Reviews Disease Primers, 2020
- Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in AustraliaAddiction, 2019
- Weekly and Monthly Subcutaneous Buprenorphine Depot Formulations vs Daily Sublingual Buprenorphine With Naloxone for Treatment of Opioid Use DisorderJAMA Internal Medicine, 2018